Starpharma Holdings (Starpharma Holdings) 5-Year EBITDA Growth Rate : -5.20% (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Starpharma Holdings 5-Year EBITDA Growth Rate?

Starpharma Holdings's EBITDA per Share for the six months ended in Dec. 2023 was $-0.03.

During the past 5 years, the average EBITDA Per Share Growth Rate was -5.20% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -3.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Starpharma Holdings was 42.20% per year. The lowest was -61.30% per year. And the median was 10.50% per year.

Competitive Comparison of Starpharma Holdings's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Starpharma Holdings's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Starpharma Holdings's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Starpharma Holdings's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Starpharma Holdings's 5-Year EBITDA Growth Rate falls into.

Starpharma Holdings 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Starpharma Holdings (OTCPK:SPHRY) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Starpharma Holdings 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Starpharma Holdings's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Starpharma Holdings (Starpharma Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starpharma Holdings Ltd (OTCPK:SPHRY) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

SPHRF:USA PQ6:Germany SPL:Australia

Address

4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067

Website

https://www.starpharma.com

Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating and VIRALEZE an antiviral nasal spray.